Clinical Trial

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

Name: Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) — clinical trial record (NCT07753603)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ORBIT

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).

Trial Details

NCT Number	NCT07753603
Lead Sponsor	Sling Therapeutics, Inc.
Conditions	Thyroid Eye Disease, TED, Graves Orbitopathy
Enrollment	130 participants
Start Date	2026-08-04
Primary Completion	2028-06-30 (estimated)
Study Completion	2030-06-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-11